OPTN - multi bottom - upcoming catalystThis is not a financial advice!
Needs to break 2 level for further up move.
Most info on the chart.
Trade carefully!
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.2628 USD
−35.48 M USD
70.99 M USD
118.99 M
About OptiNose, Inc.
Sector
CEO
Ramy A. Mahmoud
Headquarters
Yardley
Website
Founded
2000
FIGI
BBG00HS39G73
OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.
OptiNose: Maximum OptimismGood afternoon.
I would be glad if you subscribe to me in TradingView so you can be the first to read my new ideas. Overly grateful for your likes. In the comments, you can ask questions about the company.
Summary:
Technical analysis:
On the chart, we can see the completion of cor
OPTINOSE: "Rocket launch"Greetings
Summary:
Fundamental Analysis:
Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019
Company expects top-line results from one of its clinical trials evaluating XHANCE as a potential treatment for Chronic Sinusitis by the end of 2021
In Apri
OPTN Technical Analysis 🧙OptiNose Inc is a US-based specialty pharmaceutical company which focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, which utilizes proprietary breath powered exhala
OPTN is one of the best stocks I have ever seen in a while.OPTN is one of the best stocks I have ever seen in a while.
OPTN Technical Analysis 🧙OptiNose Inc is a US-based specialty pharmaceutical company which focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. The lead product of the company, XHANCE nasal spray, which utilizes proprietary breath powered exhala
OPTN Follow Your Nose!OPTN risk to reward ratio looks phenomenal right now. We have horizontal price support, uptrend price support, horizontal RSI support, hidden bullish RSI divergence, and a recent gap fill. Based on the prior signals, I'm targeting +30% gain in less than 2 weeks to fill the gap at $6.40. This setu
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of OPTN is 0.4026 USD — it has increased by 2.63% in the past 24 hours. Watch OptiNose, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange OptiNose, Inc. stocks are traded under the ticker OPTN.
OPTN stock has fallen by −8.29% compared to the previous week, the month change is a −26.16% fall, over the last year OptiNose, Inc. has showed a −70.18% decrease.
We've gathered analysts' opinions on OptiNose, Inc. future price: according to them, OPTN price has a max estimate of 5.00 USD and a min estimate of 1.00 USD. Watch OPTN chart and read a more detailed OptiNose, Inc. stock forecast: see what analysts think of OptiNose, Inc. and suggest that you do with its stocks.
OPTN reached its all-time high on Jul 9, 2018 with the price of 30.0000 USD, and its all-time low was 0.3210 USD and was reached on Nov 20, 2024. View more price dynamics on OPTN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
OPTN stock is 8.74% volatile and has beta coefficient of 3.75. Track OptiNose, Inc. stock price on the chart and check out the list of the most volatile stocks — is OptiNose, Inc. there?
Today OptiNose, Inc. has the market capitalization of 59.17 M, it has decreased by −9.33% over the last week.
Yes, you can track OptiNose, Inc. financials in yearly and quarterly reports right on TradingView.
OptiNose, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
OptiNose, Inc. revenue for the last quarter amounts to 20.44 M USD, despite the estimated figure of 22.95 M USD. In the next quarter, revenue is expected to reach 22.31 M USD.
OPTN net income for the last quarter is 393.00 K USD, while the quarter before that showed −7.58 M USD of net income which accounts for 105.18% change. Track more OptiNose, Inc. financial stats to get the full picture.
No, OPTN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 132.00 employees. See our rating of the largest employees — is OptiNose, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. OptiNose, Inc. EBITDA is −18.84 M USD, and current EBITDA margin is −31.48%. See more stats in OptiNose, Inc. financial statements.
Like other stocks, OPTN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade OptiNose, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So OptiNose, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating OptiNose, Inc. stock shows the sell signal. See more of OptiNose, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.